GATA3 mutations are frequent in breast cancer, with an estimated prevalence of 10–18% in HR + MBC; the majority are loss-of-function mutations and are associated with poor response to endocrine therapy (ET) and poor survival, as described in our previous work [5]. Here, GATA3 is linked to breast carcinoma.